P. ?-raphaël,

U. S. Daniel-bausch, Naval Medical Research

. ?-brigitte-bazin, ANRS

E. Bottieau,

F. ?-albert, Robert Debré Hospital

G. ?-rodolphe,

. Peter-redfield,

A. Laurent,

C. ?-gail,

K. ?-anne,

A. ?-caroline-semaille, F. Paris, . Van-herp, . Belgique, . Brussels et al., Britta Liedigk 15,30 , Didier Ngabo 15,29 , Martin Rudolf 15,30 , Ruth Thom 15,29 , Romy Kerber 15,30 , Martin Gabriel 15,30 , Antonino Di Caro 15,31 , Roman Wölfel 15, Takashi Kuroda) We thank Pr Dominique Lombardo, head of unit INSERM UMR_S 911, and Joseph Ciccolini (same unit, PK platform) for facilitating the implementation of favipiravir HPLC PK dosage. We also gratefully acknowledge the valuable contributions of the following persons, vol.10

, Hôpital Bicêtre, vol.5

I. Ubive and . Pasteur, Centre International de Recherche en Infectiologie, Lyon, References 1. World Health Organization. WHO | Ebola situation reports

, World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola, Ebola treatments and interventions, 2015.

S. J. Smither, L. S. Eastaugh, J. A. Steward, M. Nelson, R. P. Lenk et al., Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Res, vol.104, pp.153-155, 2014.

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, vol.105, pp.17-21, 2014.

V. Madelain, T. Nguyen, A. Olivo, X. De-lamballerie, J. Guedj et al., Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials, Clin Pharmacokinet, vol.55, pp.907-923, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01344917

, Report on the Deliberation Results (English version, Japanese Pharmaceuticals and Medical Devices Agency (PMDA), p.31, 2014.

D. Sissoko, C. Laouenan, E. Folkesson, M. Beavogui, A. Baize et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med, vol.13, p.1001967, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01327168

F. Mentré, A. Taburet, J. Guedj, X. Anglaret, S. Keïta et al., Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis, vol.15, pp.150-151, 2015.

N. Bouazza, J. Treluyer, F. Foissac, F. Mentré, A. Taburet et al., Favipiravir for children with Ebola, Lancet, vol.385, pp.603-604, 2015.

C. Bazzoli, V. Jullien, L. Tiec, C. , R. E. Mentré et al., Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action, Clin Pharmacokinet, vol.49, pp.17-45, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00461125

V. Madelain, L. Oestereich, F. Graw, T. Nguyen, X. De-lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral Res, vol.123, pp.70-77, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01196078

B. B. Gowen, E. J. Sefing, J. B. Westover, D. F. Smee, J. Hagloch et al., Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Res, vol.121, pp.132-137, 2015.

A. H. Gordon, D. E. Green, and V. Subrahmanyan, Liver aldehyde oxidase, Biochem J, vol.34, pp.764-774, 1940.

D. N. Lobo, Z. Stanga, J. A. Simpson, J. A. Anderson, B. J. Rowlands et al., Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study, Clin Sci Lond Engl, vol.101, pp.173-179, 1979.

A. M. Marty, P. B. Jahrling, and T. W. Geisbert, Viral hemorrhagic fevers, Clin Lab Med, vol.26, pp.345-386, 2006.

D. J. Roberts and R. I. Hall, Drug absorption, distribution, metabolism and excretion considerations in critically ill adults, Expert Opin Drug Metab Toxicol, vol.9, pp.1067-1084, 2013.

B. A. Boucher, G. C. Wood, and J. M. Swanson, Pharmacokinetic changes in critical illness, Crit Care Clin, vol.22, pp.255-271, 2006.

T. Hartmann, M. Terao, E. Garattini, C. Teutloff, J. F. Alfaro et al., The Impact of Single Nucleotide Polymorphisms on Human Aldehyde Oxidase, Drug Metab Dispos, vol.40, pp.856-864, 2012.

V. Madelain, J. Guedj, F. Mentré, T. Nguyen, F. Jacquot et al., Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrob Agents Chemother, p.61, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01524308